Viva Biotech Holdings 2021 SR
The report highlights Viva Biotech's 2021 performance, focusing on its expansion into CDMO services through the integration of Langhua Pharmaceutical and the acquisition of SYNthesis. Key achievements include a 201.9% revenue increase, the delivery of 13,134 new protein structures, and the incubation of 87 biotech start-ups. The company emphasized green production, setting specific targets for carbon, water, and waste reduction by 2025 and 2030. It also highlights its commitment to R&D, with investment increasing by 40%, and its inclusion in the MSCI China Small Cap Index.
Company: Viva Biotech Holdings
Sector: Health Care
Country: China
Year: 2021
Type: SR
Pages: 69
Viva Biotech Holdings
ESG Report
The report highlights Viva Biotech's 2021 performance, focusing on its expansion into CDMO services through the integration of Langhua Pharmaceutical and the acquisition of SYNthesis. Key achievements include a 201.9% revenue increase, the delivery of 13,134 new protein structures, and the incubation of 87 biotech start-ups. The company emphasized green production, setting specific targets for carbon, water, and waste reduction by 2025 and 2030. It also highlights its commitment to R&D, with investment increasing by 40%, and its inclusion in the MSCI China Small Cap Index.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Published
May 19, 2022
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Workplace Fatalities
Employees